The association of lowered efavirenz dosage and reduction in LDL and total cholesterol, makes it a possible approach for treatment of patients with metabolic or cardiovascular comorbidities.
PCSK9 inhibition with evolocumab was safe and more effective than statin monotherapy in reducing LDL-C in stable individuals with moderate CKD and clinically evident atherosclerosis.
Researchers analyzed patients’ perceptions of how reading physicians’ notes online influences factors associated with medication adherence.
When the investigators included extranodal extension in the ATA’s current PTC risk stratification system, 32.8% of patients originally categorized as low risk with ≤5 positive lymph nodes were increased to intermediate risk.
Considering more individuals are eligible for statin therapy based on 2018 cholesterol guidelines, it is important to examine the possibility that the medication may impair gonadal steroidogenesis.
Investigators examined how genetic factors associated with cardiovascular and non-cardiovascular diseases may have an effect on reported comorbid conditions.
By reducing patients’ out-of-pocket costs and encouraging doctors to use biosimilars instead of the more expensive biologic, the United States can save billions for patients and Medicare.
Sustained growth in health spending is expected to continue, with global spending projected to reach $10.6 trillion in 2030 and $15.0 trillion in 2050, but at a slower rate of growth in the majority of countries.
More than 90% of respondents indicated that the program met their learning needs and expectations.
Investigators assessed burnout-associated costs associated with physician turnover and physicians decreasing their clinical hours at national and organizational levels.
